Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Trial Profile

Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Docetaxel (Primary) ; Irinotecan (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 26 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2017, according to ClinicalTrials.gov record.
    • 26 Oct 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top